TRDA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TR

Volume

302.61K

Next Earnings

November 5th

Loading chart

TR

TRDAEntrada Therapeutics, Inc. Common Stock

TRDA

Pay with—

Available Balance0.00

TR

Mkt Cap

$186.1M

Volume

302.61K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45Entrada Therapeutics announced positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 for DMD patients amenable to exon 45 skipping. The trial met primary safety and tolerability objectives at the 5 mg/kg dose with favorable safety profile and demonstrated a 0.10% mean increase in dystrophin production. The company expects significant increases in dystrophin production at higher doses in future cohorts and plans to report Cohort 2 data (10 mg/kg) in the first half of 2027.GlobeNewswire Inc. · Oct 14, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 StudyEntrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 Phase 1/2 clinical study of ENTR-601-44 for Duchenne muscular dystrophy. The dose escalation marks progress in understanding the drug's safety and efficacy profile. Cohort 1 data is expected by year-end 2026, with Cohort 2 data anticipated in Q1 2027.GlobeNewswire Inc. · Oct 14, 2026

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Entrada Therapeutics granted 61,365 RSUs and options to purchase 19,425 shares to eight newly-hired non-executive employees under its 2025 Inducement Equity Plan, effective September 1, 2026. The options have an exercise price of $7.07 per share, with vesting schedules spanning four years for options and multiple years for RSUs, contingent on continued employment.GlobeNewswire Inc. · Sep 2, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyEntrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 2 of its ELEVATE-45-201 Phase 1/2 study at an increased dose of 10 mg/kg (up from 5 mg/kg in Cohort 1). The study evaluates ENTR-601-45 for treating Duchenne muscular dystrophy in exon 45 skipping amenable patients. The company remains on track to report Cohort 1 safety and pharmacokinetic data in mid-2026.GlobeNewswire Inc. · Jun 2, 2026

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeDelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.GlobeNewswire Inc. · May 26, 2026

INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLCLaw firm Holzer & Holzer is investigating whether Entrada Therapeutics complied with federal securities laws following disappointing topline results from its ELEVATE-44-201 Duchenne muscular dystrophy study. Cohort 1 showed a 2.36% increase in dystrophin, falling below analyst expectations and causing the stock price to decline. The firm is seeking investors who suffered losses.GlobeNewswire Inc. · May 18, 2026

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law FirmThe Schall Law Firm is investigating Entrada Therapeutics (NASDAQ: TRDA) for allegedly issuing false or misleading statements regarding Phase 1/2 clinical trial results. The company characterized topline data from the ELEVATE-44-201 study as 'positive,' but results showed only marginal protein production improvements, falling short of competitive market standards. The stock plummeted 57.3% following the May 7, 2026 announcement.GlobeNewswire Inc. · May 18, 2026

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular DiseasesEntrada Therapeutics reported progress across its RNA-based therapeutic pipeline, with multiple clinical programs in development for Duchenne muscular dystrophy (DMD) and expansion into ocular diseases. The company expects to report data from ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026, initiate a Phase 1/2 study for ENTR-601-50 by end of 2026, and submit regulatory applications for ENTR-601-51 in 2026. Entrada selected ENTR-801 as its first clinical candidate for Usher syndrome type 2A treatment and plans to nominate a second ocular candidate in 2026. The company maintains cash runway into Q3 2027.GlobeNewswire Inc. · Jan 8, 2026

Questex’s Fierce Life Sciences Announces 2025 Innovation Awards WinnersQuestex's Fierce Biotech and Fierce Pharma announced the 2025 Life Sciences Innovation Awards, recognizing groundbreaking companies across various technological domains in healthcare and biotechnology.GlobeNewswire Inc. · Nov 19, 2025

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?5AM Venture Management sold its entire 189,593 share stake in Viking Therapeutics, representing a $5.02 million position change. The sale appears to be a portfolio rebalancing rather than a lack of confidence in the company's potential.The Motley Fool · Nov 18, 2025

to start trading

TR

TRDAEntrada Therapeutics, Inc. Common Stock

TRDA

Pay with—

Available Balance0.00

Your PositionYou don't own any TRDA yet.

Related Tickers

Earnings